Last reviewed 2026-06-03 · How we verify

Acoridil (CINEPAZET)

Phase 2 active Small molecule ✓ Verified Jun 2026

Acoridil (generic name: CINEPAZET) is a cinepazet drug. It is currently in Phase 2 development.

Acoridil works by interacting with a specific biological pathway to produce its therapeutic effect.

Acoridil is a small molecule medication. It is also known by the synonyms Cinepazet, Cinepazet, and Cinepazet.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	CINEPAZET
Drug class	cinepazet
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your body's cells have a specific 'switch' that needs to be flipped to work properly. Acoridil is a small molecule that binds to this switch, helping it to turn on and off at the right times. This can help to restore balance and normal function to the cells and tissues.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Acoridil CI brief — competitive landscape report
Acoridil updates RSS · CI watch RSS

Frequently asked questions about Acoridil

What is Acoridil?

Acoridil (CINEPAZET) is a cinepazet drug.

How does Acoridil work?

Acoridil works by interacting with a specific biological pathway to produce its therapeutic effect.

What is the generic name of Acoridil?

CINEPAZET is the generic (nonproprietary) name of Acoridil.

What drug class is Acoridil in?

Acoridil belongs to the cinepazet class. See all cinepazet drugs at /class/cinepazet.

What development phase is Acoridil in?

Acoridil is in Phase 2.

Drug class: All cinepazet drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing